
ProPhase Labs PRPH
Quarterly report 2025-Q3
added 11-19-2025
ProPhase Labs EV/EBITDA Ratio 2011-2026 | PRPH
Annual EV/EBITDA Ratio ProPhase Labs
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 9.86 | -71.4 | -7.83 | -26.1 | -9.44 | -15.6 | -6.16 | -5.97 | 45.8 | -12.5 | -5.14 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 45.8 | -71.4 | -9.49 |
EV/EBITDA Ratio of other stocks in the Drug manufacturers industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Endo International plc
ENDP
|
-2.32 | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
0.599 | - | - | $ 36.6 M | ||
|
HEXO Corp.
HEXO
|
-0.524 | - | 2.45 % | $ 38.1 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
2.61 | - | -0.1 % | $ 2.03 B | ||
|
AcelRx Pharmaceuticals
ACRX
|
-0.504 | - | 7.5 % | $ 6.35 M | ||
|
DURECT Corporation
DRRX
|
0.585 | - | - | $ 50.1 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
0.353 | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
-18.4 | - | - | $ 754 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
45.3 | $ 6.23 | 4.11 % | $ 92.5 M | ||
|
Agile Therapeutics
AGRX
|
-1.28 | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
28.9 | - | - | $ 142 M | ||
|
Cronos Group
CRON
|
0.428 | $ 2.85 | 0.35 % | $ 1.09 B | ||
|
Athenex
ATNX
|
-1.1 | - | -23.39 % | $ 1.76 M | ||
|
Harrow Health
HROW
|
69.4 | $ 34.9 | -1.38 % | $ 1.28 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-6.92 | - | - | $ 2.06 B | ||
|
Catalent
CTLT
|
-64.3 | - | - | $ 11.5 B | ||
|
Eagle Pharmaceuticals
EGRX
|
160 | - | -39.89 % | $ 27.7 M | ||
|
Bausch Health Companies
BHC
|
8.84 | $ 5.32 | -1.76 % | $ 1.97 B | ||
|
Pacira BioSciences
PCRX
|
29.6 | $ 23.53 | -0.63 % | $ 1.09 B | ||
|
Organogenesis Holdings
ORGO
|
6.81 | $ 2.57 | -1.95 % | $ 326 M | ||
|
Canopy Growth Corporation
CGC
|
-4.28 | $ 1.1 | -2.23 % | $ 118 M | ||
|
Solid Biosciences
SLDB
|
-3.47 | $ 7.41 | 4.85 % | $ 648 M | ||
|
Aurora Cannabis
ACB
|
66.7 | $ 3.61 | -1.63 % | $ 198 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-4.16 | $ 1.15 | 3.15 % | $ 1.43 M | ||
|
Jupiter Wellness
JUPW
|
5.65 | - | - | $ 33.6 M | ||
|
Tilray
TLRY
|
-46 | $ 5.59 | -1.06 % | $ 3.45 B | ||
|
Lannett Company
LCI
|
-3.47 | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
-4.08 | $ 1.16 | 1.32 % | $ 111 M | ||
|
Evolus
EOLS
|
-9.74 | $ 6.63 | 0.91 % | $ 427 M | ||
|
Sundial Growers
SNDL
|
-1.27 | $ 1.48 | -0.67 % | $ 3.37 M | ||
|
Emergent BioSolutions
EBS
|
5.32 | $ 9.32 | 1.47 % | $ 499 M | ||
|
Veru
VERU
|
-3.28 | $ 2.34 | 0.86 % | $ 34.3 M | ||
|
Neoleukin Therapeutics
NLTX
|
0.799 | - | - | $ 193 M | ||
|
cbdMD
YCBD
|
-2.5 | $ 0.8 | -1.78 % | $ 3.22 M | ||
|
Assertio Holdings
ASRT
|
28.1 | $ 23.44 | -0.02 % | $ 150 M | ||
|
Radius Health
RDUS
|
-13.5 | - | - | $ 1.42 B | ||
|
PetIQ
PETQ
|
9.82 | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
-4.24 | $ 7.19 | -0.83 % | $ 284 M | ||
|
Recro Pharma
REPH
|
47.3 | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
-2.04 | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
-1.64 | $ 0.75 | 1.58 % | $ 37.5 M | ||
|
PLx Pharma
PLXP
|
-1.84 | - | -27.8 % | $ 2.56 M | ||
|
Viatris
VTRS
|
157 | $ 16.18 | 0.47 % | $ 18.8 B | ||
|
Zomedica Corp.
ZOM
|
-0.0319 | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
0.644 | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
-17.3 | $ 0.74 | -1.72 % | $ 26.6 M | ||
|
Tricida
TCDA
|
-3.64 | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
-6.14 | $ 0.81 | 4.67 % | $ 3.48 M | ||
|
TherapeuticsMD
TXMD
|
-6.57 | $ 2.07 | -1.9 % | $ 23.9 M |